Researchers sought to determine whether cilta-cel would have similar results in a real-world RRMM population as in a clinical trial population.

In a post hoc analysis of the phase 3 VISION trial, investigators analyzed PSA decline and clinical and patient-reported outcomes in patients with mCRPC receiving 177Lu-PSMA-617.

Suboptimal rates of dMMR testing and immunotherapy use suggest “a need for ongoing clinician and patient education, given the survival benefit of immunotherapy in recurrent endometrial cancer,” ...

Authors recommend patient and physician education and changes to practice guidelines and payment to overcome barriers to palliative care use.